Publications en collaboration avec des chercheurs de Sunnybrook Health Science Centre (18)

2024

  1. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods

    Scientific Reports, Vol. 14, Núm. 1

  2. Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer

    JNCI Cancer Spectrum, Vol. 8, Núm. 1

2023

  1. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

    Breast, Vol. 67, pp. 94-101

2022

  1. Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)

    Breast Cancer Research and Treatment

  2. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

2021

  1. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

    Breast Cancer Research and Treatment, Vol. 189, Núm. 3, pp. 689-699

  2. High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure

    Critical Care, Vol. 25, Núm. 1

  3. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 389-397

  4. Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study

    Journal of Intensive Care, Vol. 9, Núm. 1

  5. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 9, Núm. 5, pp. 522-532

  6. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1223-1230

  2. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

    PLoS ONE, Vol. 15, Núm. 9 September

2019

  1. New filovirus disease classification and nomenclature

    Nature Reviews Microbiology

  2. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study

    Blood, Vol. 133, Núm. 6, pp. 540-549

  3. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Emergency Heart Failure Mortality Risk Grade score performance for 7-day mortality prediction in patients with heart failure attended at the emergency department: Validation in a Spanish cohort

    European Journal of Emergency Medicine, Vol. 25, Núm. 3, pp. 169-177

2015

  1. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

    Journal of Clinical Oncology, Vol. 33, Núm. 2, pp. 141-148